Jerald P. Radich, MD
Dr. Jerald P. Radich is a Member of the Clinical Research Division and Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine in Seattle, WA. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, co-chair of the NCI/NIH Leukemia Steering Committee, and is on the Board of Scientific Counselors for the NIH Genome Research Institute. He belongs to the National Comprehensive Cancer Network (NCCN) and the EuroLeukemiaNet (ELN) CML committees, and is on the Scientific Board of the International CML Foundation. Dr. Radich’s laboratory work centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia.
Jerald P. Radich, MD, reported a financial interest/relationship or affiliation in the form of: Grants/Research Funding, Novartis Pharmaceuticals Corporation; Consultant, Ariad Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation.
Jorge E. Cortes, MD
Dr. Jorge E. Cortes is Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, where he directs the chronic myeloid leukemia and acute myeloid leukemia programs. Dr. Cortes received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, Mexico City, and has been at MD Anderson Cancer Center since 1991. Dr. Cortes, whose clinical interest focus is on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders has authored over 650 peer-reviewed medical publications. He has received numerous awards, including the Faculty Scholar Award from MD Anderson Cancer Center in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, The Dr. John J. Kenny Award from The Leukemia & Lymphoma Society in 2006, the Service to Mankind Award from The Leukemia & Lymphoma Society in 2007, and the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2007. Dr. Cortes is chief editor of Current Hematological Malignancies Reports and Co-Chief-Editor of Clinical Lymphoma, Myeloma and Leukemia. He also serves in the Editorial Board of the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia and Lymphoma, and the American Journal of Hematology. Dr. Cortes is a member of the board of directors of the Leukemia and Lymphoma Society and is President of the Latin American LeukemiaNet.
Jorge E. Cortes, MD, reported a financial interest/relationship or affiliation in the form of: Grants/Research Funding, Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer, Inc.; Consultant, Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Michael Deininger, MD, PhD
Dr. Michael Deininger is Professor and Chief of Hematology and Hematologic Malignancies for the Department of Internal Medicine and for the Huntsman Cancer Institute (HCI) at the University of Utah. He is an HCI investigator and member of the Experimental Therapeutics program. He has extensive experience treating patients with blood cancers, including chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia. Dr. Deininger received his medical degree from the University of Würzburg Medical School in Germany in 1990. In 1995, he obtained a grant to enroll in the PhD program at Imperial College, London. In August 2010, Dr. Deininger became the M.M. Wintrobe Professor of Medicine at the University of Utah and was appointed Chief of the Division of Hematology and Hematologic Malignancies.
Dr. Deininger’s scientific focus is leukemia, specifically myeloproliferative neoplasms including CML. As a clinician-scientist with a translational research focus, Dr. Deininger is heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance and new molecular therapies in leukemia. Dr. Deininger’s work describing the selective effects of imatinib on CML cells provided the rationale for clinical trials that led to the approval of the drug as the first molecularly-based therapy for leukemia. Current work in his lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets and developing more specific signal transduction inhibitors. Dr. Deininger’s work encompasses more than 170 articles in the peer-reviewed literature, including journals like Blood, Journal of Clinical Investigation and the New England Journal of Medicine. He has co-authored more than 10 book chapters, with contributions in leading textbooks such as DeVita’s Principles of Oncology. He is a regular speaker at major international scientific meetings, such as the American Society of Hematology and the European Hematology Association and a peer-reviewer for journals like Nature Genetics and Cancer Cell. His honors include the Alexandra Kefalides Prize for Leukemia Research and membership on the editorial board of Blood, the leading journal in hematology.
Michael W.N. Deininger, MD, PhD, reported a financial interest/relationship or affiliation in the form of: Grants/Research Funding, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme, Inc.; Consultant, Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation.
Harry P. Erba, MD, PhD
Dr. Harry P. Erba serves as Director of the Hematologic Malignancy Program and the Associate Director for Clinical Research in the Comprehensive Cancer Center. He has been an active member in the SWOG Leukemia Committee for over a decade. In October 2012, he was appointed Chairman of the SWOG Leukemia Committee and now serves on the NCI Leukemia Steering Committee. Dr. Erba has also served on the National Comprehensive Cancer Network (NCCN) Practice Guidelines Committees for acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and myeloid growth factors.
Dr. Erba has focused on the assessment of novel therapies in acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndromes. He has been involved in numerous clinical trials in these hematologic malignancies, led many national trials as a chair or co-chair, and played major roles in the development of several new drugs. His work has been published in Nature, Cell, Journal of Clinical Oncology, Blood, Cancer Research and British Journal of Haematology, among others. In addition to 47 peer-reviewed publications, he has authored five book chapters and has lectured extensively in the US, Canada, South America, Europe and Japan. Dr. Erba received a Bachelor of Science degree in biology from Yale University in 1979 and his medical and doctorate degrees from Stanford University in 1988.
Harry P. Erba, MD, PhD, reported a financial interest/relationship or affiliation in the form of: Grants/Research Funding, Amgen, Inc., Celator Pharmaceuticals, Millennium Pharmaceuticals, Inc., Seattle Genetics, Inc.; Consultant, Amgen, Inc., Incyte Corporation, Novartis Pharmaceuticals Corporation, Seattle Genetics, Inc.; Speakers' Bureau, Incyte Corporation, Novartis Pharmaceuticals Corporation.
Neil P. Shah, MD, PhD
Dr. Neil Shah is the Edward S. Ageno Distinguished Professor of Hematology/Oncology at the University of California, San Francisco (UCSF), and leader of the Hematopoietic Malignancies Program at the UCSF Helen Diller Family Comprehensive Cancer Center. He is a diplomate in internal medicine, medical oncology, as well as hematology of the American Board of Internal Medicine. Dr. Shah’s research interests focus on understanding molecular mechanisms of disease response and resistance to targeted therapeutics in human myeloid malignancies. He has authored or co-authored numerous publications largely focused on chronic myeloid leukemia and acute myeloid leukemia.
Dr. Shah received his doctorate in microbiology and molecular genetics at the University of California, Los Angeles (UCLA), and his medical degree from the UCLA School of Medicine. He continued his postdoctoral training at UCLA with an internship and residency in internal medicine, followed by a fellowship in hematology and oncology.
Neil P. Shah, MD, PhD, reported a financial interest/relationship or affiliation in the form of: Grants/Research Funding, Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb Company.
Amit Verma, MD
Associate Professor, Department of Medicine (Oncology)
Associate Professor, Department of Developmental & Molecular Biology
Albert Einstein College of Medicine
Director, Division of Hematologic Malignancies
Montefiore Medical Center
Bronx, New York
Amit K. Verma, MD, is Associate Professor of Oncology and of Developmental and Molecular Biology at the Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, Bronx, New York. He is a recipient of a Young Investigator Award from the American Society of Clinical Oncology; an American Cancer Society Research Scholar Award; and a Leukemia and Lymphoma Scholar in Clinical Research Award. Dr. Verma trained at the University of Illinois, Champaign, Illinois, and previously was a member of the faculty at the University of Texas Southwestern Medical Center, Houston, Texas.
Amit Verma, MD reported a financial interest/relationship or affiliation in the form of: Speakers’ Bureau: Celgene.